Prevalence of nephropathy and proximal tubule disorder in human immunodeficiency virus patients under tenofovir therapy
Introduction: Tenofovir is a common therapy in human immunodeficiency virus (HIV) patients. Objective: This study was carried out to determine the prevalence of nephropathy and proximal tubule disorder in HIV patients under tenofovir therapy. Patients and Methods: In this study, 160 HIV patients und...
Gespeichert in:
Veröffentlicht in: | Journal of nephropharmacology 2022, Vol.11 (1), p.e11-e11 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Introduction:
Tenofovir is a common therapy in human immunodeficiency virus (HIV) patients.
Objective:
This study was carried out to determine the prevalence of nephropathy and proximal tubule disorder in HIV patients under tenofovir therapy.
Patients and Methods:
In this study, 160 HIV patients under tenofovir therapy were enrolled and the prevalence of nephropathy and proximal tubule disorder was determined and compared.
Results:
We found, the proximal tubule involvement in 25%, 6.8%, 2.2% and 0% in first year, 2–5 years , 6–10 years and 11–18 years of disease involvement respectively, (
P
= 0.02). The mean glomerular filtration rate (GFR) diminution was 2.15%, 10.53%, 12.6% and 17.79%, in the first, 2–5, 6–10, and 11–18 years, respectively, again showing a significant difference between years (
P
= 0.02). Proteinuria was seen in 13.1% of patients.
Conclusion:
We concluded that GFR diminution and proximal tubule involvement are common and important to be managed in HIV-positive patients under tenofovir therapy, and discontinuation of drug has no positive effect on GFR. |
---|---|
ISSN: | 2345-4202 2345-4202 |
DOI: | 10.34172/npj.2022.11 |